A pilot study conducted at the European Respiratory Society (ERS) congress in Stockholm in September showed that health care professionals are very positive about our latest inhaler technology range. The pMDI Asmair® was particularly positively evaluated on its ease of use and design, as well as on its crucial features: the single increment dose counter and the assisted firing of the dose. Moreover, the respondent expressed a great willingness to prescribe a BAI in favour of more cost effective inhalers on the market. These perspectives are very promising for our BAI Insulair®.

Read more about the pilot survey here or learn more about the inhalation technology range here

Return to newsletter